Peter Rankin and Andrew Tepperman published an article entitled “Biosimilars: economics and intellectual property,” which appeared in IPPro Life Sciences. The article discusses new challenges and opportunities innovators face relating to their IP rights with the onset of biosimilars. To read the article, click the link below.
CAR-T vs. bispecific therapies: Two growth stories are reshaping hematologic oncology
While both CAR-T cell therapies and bispecific antibodies have experienced rapid growth in recent years, new analysis by CRA’s Chris Nüesch suggests that the...